Physician profile
Jeffrey K Gin
NPI 1225140759
$3,801.92
in general payments reported to CMS, 2019-2025
28 companies · $709 in 2025
The $709 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.67 · 2020: $203 · 2021: $749 · 2022: $444 · 2023: $666 · 2024: $954 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.51 | 2021-2024 | |
| Lilly USA, LLC | $552.33 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $536.13 | 2020-2024 | Jardiance |
| Amgen INC. | $223.56 | 2021-2025 | Krystexxa, Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $217.62 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $206.85 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.74 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $152.69 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $108.59 | 2024-2025 | Freestyle Libre 3 |
| Pfizer INC. | $105.22 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $91.84 | 2024-2025 | Airsupra |
| Gilead Sciences, INC. | $79.87 | 2025 | |
| Allergan, INC. | $62.68 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $57.22 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $51.08 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $49.19 | 2021 | |
| Merck Sharp & Dohme LLC | $44.72 | 2021 | |
| Sanofi Pasteur INC. | $34.89 | 2019-2023 | |
| Vertex Pharmaceuticals Incorporated | $31.92 | 2025 | |
| Dexcom, INC. | $25.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.39 | 2023 | |
| Almatica Pharma LLC | $22.91 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.51 | 2021 | |
| Breathe Technologies, INC. | $17.06 | 2019 | |
| Shire North American Group INC | $16.18 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.53 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $14.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.